Subsequent Malignant Neoplasms after Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1 SUPPL., 2012, Pages

  Socié, Gerard ^a,b   Baker, K Scott ^c   Bhatia, Smita ^d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c Fred Hutchinson Cancer Research Center   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BETA CATENIN; BUSULFAN; CD3 ANTIBODY; CHLORAMBUCIL; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACARBAZINE; DNA; DOXORUBICIN; GYRASE INHIBITOR; IFOSFAMIDE; IMMUNOSUPPRESSIVE AGENT; LOMUSTINE; MELPHALAN; MISMATCH REPAIR PROTEIN; PROTEIN KINASE B; PROTEIN MDM2; RITUXIMAB; STEROID; THIOTEPA; THYMOCYTE ANTIBODY; TUMOR SUPPRESSOR PROTEIN; UNINDEXED DRUG; WNT PROTEIN; XENOBIOTIC AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BASAL CELL CARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVOR; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CORTICOSTEROID THERAPY; CYTOGENETICS; CYTOPENIA; DISEASE FREE SURVIVAL; DNA REPAIR; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; EPSTEIN BARR VIRUS; EXCISION REPAIR; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA REMISSION; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MISMATCH REPAIR; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; OVERT LEUKEMIA; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDER; PREVALENCE; QUALITY OF LIFE; RADIATION EXPOSURE; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SKIN CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STEM CELL MOBILIZATION; SUBSEQUENT MALIGNANT NEOPLASM; THYROID CANCER; TUMOR SUPPRESSOR GENE; WHOLE BODY RADIATION;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASMS, SECOND PRIMARY; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855398470     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.005     Document Type: Article

References (98)

1. Bhatia S., Ramsay N.K.C., Steinbuch M., et al. Malignant neoplasms following bone marrow transplantation. Blood 1996, 87:3633-3639.
2. Curtis R.E., Rowlings P.A., Deeg H.J., et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997, 336:897-904.
3. Krishnan A., Bhatia S., Slovak M.L., et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000, 95:1588-1593.
4. Rizzo J.D., Curtis R.E., Socie G., et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009, 113:1175-1183.
5. Friedman D.L., Rovo A., Leisenring W., et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood 2008, 111:939-944.
6. Cohen A., Rovelli A., Merlo D.F., et al. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol 2007, 25:2449-2454.
7. Witherspoon R.P., Fisher L.D., Schoch G., et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989, 321:784-789.
8. Gilliland D.G., Gribben J.G. Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation. Biol Blood Marrow Transplant 2002, 8:9-16.
9. Milligan D.W., Ruiz De Elvira M.C., Kolb H.J., et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol 1999, 106:1020-1026.
10. Stone R.M. Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress. Blood 1994, 83:3437-3440.
11. Friedberg J.W., Neuberg D., Stone R.M., et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999, 17:3128-3135.
12. Bhatia S., Robison L.L., Francisco L., et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005, 105:4215-4222.
13. Witherspoon R.P., Deeg H.J. Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia. Haematologica 1999, 84:1085-1087.
14. Bloomfield C.D., Archer K.J., Mrozek K., et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002, 33:362-378.
15. Litzow M.R., Tarima S., Perez W.S., et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2009, 115:1850-1857.
16. Landgren O., Gilbert E.S., Rizzo J.D., et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009, 113:4992-5001.
17. Curtis R.E., Travis L.B., Rowlings P.A., et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999, 94:2208-2216.
18. Schouten H.C., Hopman A.H., Haesevoets A.M., Arends J.W. Large-cell anaplastic non-Hodgkin's lymphoma originating in donor cells after allogenic bone marrow transplantation. Br J Haematol 1995, 91:162-166.
19. Rowlings P.A., Curtis R.E., Passweg J.R., et al. Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation. J Clin Oncol 1999, 17:3122-3127.
20. Bhatia S., Louie A.D., Bhatia R., et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001, 19:464-471.
21. Kolb H.J., Socie G., Duell T., et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999, 131:738-744.
22. Baker K.S., DeFor T.E., Burns L.J., Ramsay N.K., Neglia J.P., Robison L.L. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003, 21:1352-1358.
23. Shimada K., Yokozawa T., Atsuta Y., et al. Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis. Bone Marrow Transplant 2005, 36:115-121.
24. Gallagher G., Forrest D.L. Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer 2007, 84-92.
25. Leisenring W., Friedman D.L., Flowers M.E., Schwartz J.L., Deeg H.J. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 2006, 24:1119-1126.
26. Socie G., Stone J.V., Wingard J.R., et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999, 341:14-21.
27. Wingard J.R., Majhail N.S., Brazauskas R., et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011, 29:2230-2239.
28. Martin P.J., Counts G.W., Appelbaum F.R., et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010, 28:1011-1016.
29. Duell T., van Lint M.T., Ljungman P., et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med 1997, 126:184-192.
30. Bhatia S., Francisco L., Carter A., et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007, 110:3784-3792.
31. Socie G., Henry-Amar M., Cosset J.M., Devergie A., Girinsky T., Gluckman E. Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood 1991, 78:277-279.
32. Deeg H.J., Socie G., Schoch G., et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996, 87:386-392.
33. Socie G., Curtis R.E., Deeg H.J., et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000, 18:348-357.
34. Curtis R.E., Metayer C., Rizzo J.D., et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005, 105:3802-3811.
35. Majhail N.S., Brazauskas R., Rizzo J.D., et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 2011, 117:316-322.
36. Schwartz J.L., Kopecky K.J., Mathes R.W., Leisenring W.M., Friedman D.L., Deeg H.J. Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation. Radiat Res 2009, 171:155-163.
37. Kenney L.B., Yasui Y., Inskip P.D., et al. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med 2004, 141:590-597.
38. Travis L.B., Hill D., Dores G.M., et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005, 97:1428-1437.
39. Henderson T.O., Whitton J., Stovall M., et al. Secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2007, 99:300-308.
40. van Leeuwen F.E., Travis L.B. Second Cancers. Cancer: Principles and Practice of Oncology 2005, 2575-2602. Lippincott Williams and Wilkins, Philadelphia, PA. 7th ed. H.S. DeVita, S.A. Rosenberg (Eds.).
41. Limacher J.M., Frebourg T., Natarajan-Ame S., Bergerat J.P. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 2001, 96:238-242.
42. Alter B.P. Cancer in Fanconi anemia, 1927-2001. Cancer 2003, 97:425-440.
43. Rosenberg P.S., Alter B.P., Ebell W. Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica 2008, 93:511-517.
44. Kalow W., Ozdemir V., Tang B.K., Tothfalusi L., Endrenyi L. The science of pharmacological variability: an essay. Clin Pharmacol Ther 1999, 66:445-447.
45. Evans W.E., McLeod H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003, 348:538-549.
46. Berwick M., Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000, 92:874-897.
47. Goode E.L., Ulrich C.M., Potter J.D. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002, 11:1513-1530.
48. Bhatti P., Doody M.M., Alexander B.H., et al. Breast cancer risk polymorphisms and interaction with ionizing radiation among U.S. radiologic technologists. Cancer Epidemiol Biomarkers Prev 2008, 17:2007-2011.
49. Bhatti P., Struewing J.P., Alexander B.H., et al. Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. Radiologic technologists. Int J Cancer 2008, 122:177-182.
50. Rajaraman P., Bhatti P., Doody M.M., et al. Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists. Int J Cancer 2008, 123:2713-2716.
51. Worrillow L.J., Travis L.B., Smith A.G., et al. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res 2003, 9:3012-3020.
52. Allan J.M., Smith A.G., Wheatley K., et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 2004, 104:3872-3877.
53. Mertens A.C., Mitby P.A., Radloff G., et al. XRCC1 and glutathione-S-transferase gene polymorphisms and susceptibility to radiotherapy-related malignancies in survivors of Hodgkin disease. Cancer 2004, 101:1463-1472.
54. Worrillow L.J., Smith A.G., Scott K., et al. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. J Med Genet 2008, 45:142-146.
55. McFadyen M.C., Melvin W.T., Murray G.I. Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 2004, 3:363-371.
56. Park J.Y., Shigenaga M.K., Ames B.N. Induction of cytochrome P4501A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin or indolo(3,2-b)carbazole is associated with oxidative DNA damage. Proc Natl Acad Sci USA 1996, 93:2322-2327.
57. Hayes J.D., Flanagan J.U., Jowsey I.R. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005, 45:51-88.
58. Allan J.M., Wild C.P., Rollinson S., et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA 2001, 98:11592-11597.
59. Collins A., Harrington V. Repair of oxidative DNA damage: assessing its contribution to cancer prevention. Mutagenesis 2002, 17:489-493.
60. Karran P., Offman J., Bignami M. Human mismatch repair, drug-induced DNA damage, and secondary cancer. Biochimie 2003, 85:1149-1160.
61. Casorelli I., Offman J., Mele L., et al. Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. DNA Repair (Amst) 2003, 2:547-559.
62. Seedhouse C.H., Das-Gupta E.P., Russell N.H. Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia. Leukemia 2003, 17:83-88.
63. Zhu Y.M., Das-Gupta E.P., Russell N.H. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood 1999, 94:733-740.
64. Horiike S., Misawa S., Kaneko H., et al. Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype. Leukemia 1999, 13:1235-1242.
65. Fishel R., Lescoe M.K., Rao M.R., et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993, 75:1027-1038.
66. Brentnall T.A., Rubin C.E., Crispin D.A., et al. A germline substitution in the human MSH2 gene is associated with high-grade dysplasia and cancer in ulcerative colitis. Gastroenterology 1995, 109:151-155.
67. Worrillow L.J., Allan J.M. Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia. Oncogene 2006, 25:1709-1720.
68. O'Driscoll M., Jeggo P.A. The role of double-strand break repair-insights from human genetics. Nat Rev Genet 2006, 7:45-54.
69. Baumann P., West S.C. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci 1998, 23:247-251.
70. Jawad M., Seedhouse C.H., Russell N., Plumb M. Polymorphisms in human homeobox HLX1 and DNA repair RAD51 genes increase the risk of therapy-related acute myeloid leukemia. Blood 2006, 108:3916-3918.
71. Seedhouse C., Faulkner R., Ashraf N., Das-Gupta E., Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 2004, 10:2675-2680.
72. Bishop D.K., Ear U., Bhattacharyya A., et al. Xrcc3 is required for assembly of Rad51 complexes invivo. J Biol Chem 1998, 273:21482-21488.
73. Liu N., Lamerdin J.E., Tebbs R.S., et al. XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages. Mol Cell 1998, 1:783-793.
74. Tebbs R.S., Zhao Y., Tucker J.D., et al. Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene. Proc Natl Acad Sci USA 1995, 92:6354-6358.
75. Pierce A.J., Johnson R.D., Thompson L.H., Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 1999, 13:2633-2638.
76. Matullo G., Palli D., Peluso M., et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001, 22:1437-1445.
77. Au W.W., Salama S.A., Sierra-Torres C.H. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003, 111:1843-1850.
78. Caldecott K.W., McKeown C.K., Tucker J.D., Ljungquist S., Thompson L.H. An interaction between the mammalian DNA repair protein XRCC1 and DNA ligase III. Mol Cell Biol 1994, 14:68-76.
79. Kubota Y., Nash R.A., Klungland A., Schar P., Barnes D.E., Lindahl T. Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein. EMBO J 1996, 15:6662-6670.
80. Seedhouse C., Bainton R., Lewis M., Harding A., Russell N., Das-Gupta E. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood 2002, 100:3761-3766.
81. Nelson H.H., Kelsey K.T., Mott L.A., Karagas M.R. The XRCC1 Arg399Gln polymorphism, sunburn, and non-melanoma skin cancer: evidence of gene-environment interaction. Cancer Res 2002, 62:152-155.
82. Ellis N.A., Huo D., Yildiz O., et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 2008, 112:741-749.
83. Knight J.A., Skol A.D., Shinde A., et al. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood 2009, 113:5575-5582.
84. Best T., Li D., Skol A.D., et al. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med 2011, 17:941-943.
85. Children's Oncology Group. Long-Term Follow-up Guidelines for Survivors of Childhood A, and Young Adult Cancers. Version 3.0. Accessed August 2, 2011.
86. Rizzo J.D., Wingard J.R., Tichelli A., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2006, 12:138-151.
87. Bhatia S., Meadows A.T., Robison L.L. Second cancers after pediatric Hodgkin's disease. J Clin Oncol 1998, 16:2570-2572.
88. Khera N., Chow E.J., Leisenring W.M., et al. Factors associated with adherence to preventive care practices among hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant 2011, 17:995-1003.
89. Stockfleth E., Ulrich C., Meyer T., Christophers E. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res 2002, 160:251-258.
90. Romero-Vargas M.E., Flores-Cortes M., Valera Z., et al. Cancers of new appearance in liver transplant recipients: incidence and evolution. Transplant Proc 2006, 38:2508-2510.
91. Abu-Elmagd K.M., Mazariegos G., Costa G., et al. Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: improved outcomes with new outlooks. Transplantation 2009, 88:926-934.
92. Byers T., Nestle M., McTiernan A., et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2002, 52:92-119.
93. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638.
94. Ness K.K., Bhatia S., Baker K.S., et al. Performance limitations and participation restrictions among childhood cancer survivors treated with hematopoietic stem cell transplantation: the bone marrow transplant survivor study. Arch Pediatr Adolesc Med 2005, 159:706-713.
95. Baker K.S., Gurney J.G., Ness K.K., et al. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood 2004, 104:1898-1906.
96. Fraser C.J., Bhatia S., Ness K., et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood 2006, 108:2867-2873.
97. Baker K.S., Ness K.K., Steinberger J., et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood 2007, 109:1765-1772.
98. Baker K.S., Chow E.J., Goodman P., et al. Adverse impact of hematopoietic cell transplantation (HCT) on body composition and insulin resistance is associated with increased cardiovascular risk. Biol Blood Marrow Transplant 2011, 17(suppl 1):S174-S175.